Market Access Obstructs Newer Biologic and JAK Adoption in Rheumatoid Arthritis
Download Report Overview Despite frequent involvement with payers for the approval of biologics/JAKs in RA, rheumatologists report that their use is heavily impacted by the negative reimbursement and access environment, according to a recent report from Spherix Global Insights. August 19, 2016 – Cambridge, Massachusetts. While the majority of surveyed rheumatologists (n=100) report that access […]
User Base for Novartis’ Cosentyx in Psoriatic Arthritis Significantly Expands as Rheumatologists Report High Satisfaction
Download Report Overview At nearly six months post launch, three-quarters of US rheumatologists report having prescribed Cosentyx, a significant increase from the 24% who reported use at one month post-launch, according to a recent report from Spherix Global Insights. August 11, 2016 – Cambridge, Massachusetts. US rheumatologists are increasingly adopting Novartis’ IL-17 inhibitor, Cosentyx, into […]
Neurologists Report Increasing Payer Pressure for Disease-Modifying Therapies, Resulting in Suboptimal Treatment for Some Patients with Multiple Sclerosis
Download Report Overview August 1, 2016 – Cambridge, MA- In the Q2 update of RealTime Dynamix™: Multiple Sclerosis, roughly one-quarter of the respondents reported increased payer restrictions for Teva’s Copaxone while restrictions have eased somewhat for Sandoz’s Glatopa, Novartis’ Extavia and Biogen’s Tecfidera. While half of the neurologists agreed that payers are becoming more aggressive […]
A Waltz with Taltz – Dermatologists Report Early Adoption of Ixekizumab in Psoriasis
Download Report Overview At just over one month post launch, one-third of dermatologists report having prescribed Eli Lilly’s IL-17 inhibitor, Taltz, according to a recent report from Spherix Global Insights. July 26, 2016 – Cambridge, Massachusetts. At approximately six weeks after launch of Eli Lilly’s Taltz, one-third of surveyed dermatologists (n=99) report trialling the latest […]
RealTime Dynamix™: Hyperkalemia, June 2016
The sixth monthly update on the launch of Veltassa and the evolution of the Hyperkalemia market provided by 101 Nephrologists. Download Report Overview About Spherix Global Insights Spherix Global Insights is a newly established business intelligence and market research company headquartered in Cambridge, MA with EU offices in Zug, Switzerland. We specialize in renal, autoimmune, […]
RealTime Dynamix™: Renal Anemia, June 2016
Monthly report covering the dialysis and chronic kidney disease market for ESAs and IV Iron. Additional insight on the development pipeline including receptivity to biosimilar ESAs and growing awareness of a novel class of anemia agents, the HIF-PH inhibitors. n=104 nephrologists Download Report Overview About Spherix Global Insights Spherix Global Insights is a newly established […]
RealTime Dynamix™: Bone and Mineral Metabolism, June 2016
Monthly refresh for the US phosphate binder and secondary hyperparathyroidism market wth launch metrics for Auryxia and Velphoro with pre-launch insight on Parsabiv, Amgen’s IV calcimimetic. n=104 nephrologists Download Report Overview About Spherix Global Insights Spherix Global Insights is a newly established business intelligence and market research company headquartered in Cambridge, MA with EU offices […]
Relypsa’s Veltassa Continues An Upward Trajectory Among Nephrologists But Familiarity And Use Is More Muted Among Cardiologists
Download Report Overview The hyperkalemia market is poised for a massive paradigm shift as clinicians begin to embrace the concept of chronic treatment, according to several reports by Spherix Global Insights, GmbH ZUG, Switzerland, May 18, 2016 /PRNewswire/ — According to the most recent monthly nephrology survey fielded at the end of April (n=112), the […]
Momenta’s Glatopa Shown to Have a Weak Market Position Compared to Teva’s Copaxone According to Recent Study by Spherix Global Insights
Download Report Overview The research, based on input from 85 US based physicians, also reveals continuing pressure on platform injectables in favor of earlier use of oral agents such as Sanofi’s Aubagio, Novartis’ Gilenya and Biogen’s Tecfidera ZUG, Switzerland, May 18, 2016 /PRNewswire/ — A recent study conducted by Spherix Global Insights found that Teva’s Copaxone continues to […]
2016 Nephrology Publications
Our focus will be on bone and mineral metabolism, renal anemia, hyperkalemia, diabetic nephropathy, chronic kidney disease and dialysis. Monthly survey of highly dynamic markets, tracking brand usage, awareness, industry contacts and evolving perceptions. RealTime Dynamix: Bone and Mineral US 2016 RealTime Dynamix: Renal Anemia US 2016 RealTime Dynamix: Hyperkalemia US 2016 […]
